Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Drugs Today (Barc). 2021 Mar;57(3):209-218. doi: 10.1358/dot.2021.57.3.3251715.ABSTRACTNeuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (C...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage
Drugs Today (Barc). 2021 Mar;57(3):219-239. doi: 10.1358/dot.2021.57.3.3250287.ABSTRACTAcquired hypofibrinogenemia is a frequent cause of maintained bleeding in perioperative high-risk settings. Loss, consumption and dilution under resuscitation fluid therapy are the principal causes for fibrinogen depletion. Severe hypofibrinogenemia is frequently associated with an early bleeding complication that cannot be reliably avoided with high-ratio plasma transfusion strategies. Real-time monitoring with viscoelastic hemostatic assays is a useful tool for timely diagnosis and treatment of detected coagulopathies. Replenishment of...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: T Koller A Parera Ruiz M Diaz-Ricart A M G ómez Caro Source Type: research

Dostarlimab for the treatment of endometrium cancer and other solid tumors
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.ABSTRACTThe use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lun...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: J Rubio-P érez R Hern ández T Hern ández B Doger V Casado V Moreno Source Type: research

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment
Drugs Today (Barc). 2021 Mar;57(3):199-208. doi: 10.1358/dot.2021.57.3.3251711.ABSTRACTEffective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in c...
Source: Drugs of Today - March 17, 2021 Category: Drugs & Pharmacology Authors: A Gomaa N Allam I Waked Source Type: research